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SUMMARY
In 2014, the Food and Drug Administration approved a new human papillomavirus 9-valent
vaccine (9vHPV), targeting nine HPV types: HPV types 6, 11, 16, and 18, which are also
targeted by the quadrivalent HPV vaccine (qHPV), plus ﬁve additional high cancer risk HPV
types (HPV types 31, 33, 45, 52, and 58). The aim of the current study was to systematically
retrieve, qualitatively and quantitatively pool, as well as critically appraise all available evidence
on 9vHPV from randomized controlled trials (RCTs). We conducted a systematic review of the
literature on 9vHPV efﬁcacy, immunogenicity and safety, as well as a systematic search of
registered, completed, and ongoing RCTs. We retrieved and screened 227 records for eligibility.
A total of 10 publications reported on RCTs’ results on 9vHPV and were included in the review.
Sixteen RCTs on 9vHPV have been registered on RCT registries. There is evidence that 9vHPV
generated a response to HPV types 6, 11, 16 and 18 that was non-inferior to qHPV. Vaccine
efﬁcacy against ﬁve additional HPV type-related diseases was directly assessed on females aged
16–26 years (risk reduction against high-grade cervical, vulvar or vaginal disease = 96·7%, 95%
CI 80·9%–99·8%). Bridging efﬁcacy was demonstrated for males and females aged 9–15 years
and males aged 16–26 years (the lower bound of the 95% CIs of both the geometric mean titer
ratio and difference in seroconversion rates meeting the criteria for non-inferiority for all HPV
types). Overall, 9vHPV has been proved to be safe and well tolerated. Other RCTs addressed:
9vHPV co-administration with other vaccines, 9vHPV administration in subjects that previously
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received qHPV and 9vHPV efﬁcacy in regimens containing fewer than three doses. The inclusion
of additional HPV types in 9vHPV offers great potential to expand protection against HPV
infection. However, the impact of 9vHPV on reducing the global burden of HPV-related disease
will greatly depend on vaccine uptake, coverage, availability, and affordability.
Key words: Cancer prevention, HPV, human papillomavirus 9-valent vaccine, systematic review.
BACKGROUND
The latest World Health Organization (WHO) global
estimates report 14·1 million new cancer cases to occur
every year, 8·2 million cancer deaths and 32·6 million
people living with cancer; these ﬁgures are projected
to increase to 15·2 million new cases and 8·9 deaths
by 2035 [1]. Cancers attributable to infections –
which can be targeted by immunization-based pri-
mary prevention interventions – account for 16% of
this burden [2]. Cervical cancer is the fourth most
common cancer in women, and the seventh overall,
with an estimated 528 000 new cases and 266 000
deaths in 2012 [1]. Human papillomavirus (HPV) car-
cinogenicity has been solidly established for cervical
cancer; HPV infection is responsible for virtually all
cervical cancers and for a large number of other
genitourinary cancers including vulvar, vaginal, penile
and anal cancer, as well as for oropharyngeal cancers,
resulting in HPV being responsible for a signiﬁcant
proportion of worldwide cancer burden [3–10].
There are more than 100 types of HPV, of which at
least 12 have been identiﬁed as high-risk oncogenic
types and are vaccine targets. HPV types 16 and 18
were classiﬁed as carcinogens by the International
Agency for Research on Cancer (IARC) in 1995 [11]
and are reported to account for approximately 70%
of cervical cancers. HPV types 31, 33, 35, 39, 45, 51,
52, 56, 58, and 59 were included in the IARC carcino-
gens group in 2011 [12] and are reported to account
for 30% of cervical cancers [13–17].
The quadrivalent (against HPV types 6, 11, 16, and
18, qHPV) and bivalent (against HPV types 16 and 18,
bHPV) vaccines were licensed in the US in 2006 and
2009 and have since been widely introduced in immun-
ization schedules at the global level. In Europe, qHPV
is approved for use in males and females from the age
of 9 years to protect against precancerous lesions in the
cervix, vulva, vagina and anus, cervical and anal can-
cers and genital warts [18]; bHPV is approved for use
in males and females from the age of 9 years to protect
against cervix or anus cancers and against precancerous
lesions in the genital area [19].
A second-generation HPV 9-valent vaccine (9vHPV)
targeting ﬁve additional HPV types (against HPV types
6, 11, 16, 18, 31, 33, 45, 52, and 58) was approved in
December 2014 by the US Food and Drug
Administration (FDA) [20] and granted marketing
authorization by the European Commission in June
2015 [21]. In Europe, 9vHPV is approved for use in
males and females from the age of 9 years to protect
against precancerous lesions and cancers of the cervix,
vulva, or vaginaandanus, andagainst genitalwarts [22].
Currently, 9vHPV is also licensed inCanada,Australia,
Chile, and Hong-Kong and, more recently, Ecuador,
South Korea, and New Zealand. The US Advisory
Committee on Immunization Practices (ACIP) recom-
mended 9vHPV as one of three HPV vaccines that can
be used for routine vaccination in February 2015 [23]
and, fromMay 2017, after all lots of qHPV have expired,
will be the only HPV vaccine available in the USA [24].
The potential public health impact and cost-
effectiveness of 9vHPV has been explored by mathem-
atical models under different efﬁcacy, cost, and vaccine
coverage scenarios [25–30]. As clinical trial data is cur-
rently accumulating on 9vHPV efﬁcacy, immunogen-
icity, and safety in different age groups and study
populations, as well as on different dose regimens
and co-administrations, no systematic assessment has
been conducted so far to pool the available evidence
on the topic. The aim of the current study is to system-
atically retrieve, qualitatively and quantitatively pool,
and critically appraise all available evidence from ran-
domized controlled trials (RCTs) on 9vHPV.
METHODS
We conducted a systematic review of the available
published evidence on the efﬁcacy, immunogenicity,
and safety of 9vHPV, as well as a systematic search
of the registered, completed, active, and/or ongoing
clinical trials (RCTs) on 9vHPV. The review’s meth-
ods were deﬁned in advance following the PRISMA
(Prepared Items for Systematic Reviews and Meta-
Analysis) guidelines [31].
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Search methods for studies’ identiﬁcation
Published studies were identiﬁed by searching the elec-
tronic databases Medline, Embase and the Cochrane
Library. The database search strategies were built
around 9vHPV-related free-text key words. The
search strategy was ﬁrst developed for Medline and
then adapted for use in Embase and the Cochrane
Library. All three search strategies are available as
online supplementary material (Table S1). In add-
ition, further studies were retrieved from reference list-
ing of relevant articles and consultation with experts
in the ﬁeld.
Registered clinical trials were identiﬁed searching
the clinical trials’ registries and platforms: the WHO
ICTRP (International Clinical Trials Registry
Platform), the ClinicalTrials.gov registry, the Cochrane
Central Register of Controlled Trials and the EU
Clinical Trial Register (all registries’ search strategies are
available as online supplementary material, Table S1).
Inclusion criteria and outcomes
All published clinical trials’ on 9vHPV were included
in the systematic review of the literature. All other
study designs were considered not eligible for inclu-
sion, neither were reviews or opinion papers. We con-
sidered the following primary outcomes: all measures
of 9vHPV’s clinical efﬁcacy, immunogenicity, and
safety in all possible age groups and study popula-
tions. Studies published in English through August
25, 2016 were included.
In our systematic search of the registered RCTs, we
retrieved all RCT protocols through August 25, 2016
reporting 9vHPV to be administered in any of the
RCTs’ arms. All age groups, study populations, com-
parisons, and dose regimens were included.
Collection and analysis
All identiﬁed studies were independently reviewed for
eligibility by three authors (P.C., V.C., and A.O.) in a
two-step-based process; a ﬁrst screen was performed
based on title and abstract while full texts were
retrieved for the second screen. At both stages dis-
agreements by reviewers were resolved by consensus.
Data were extracted by two authors (P.C. and V.C.)
supervised by a third author (A.O.), using a standar-
dised data extraction spreadsheet. The data extraction
spreadsheet was piloted on three randomly selected
papers and modiﬁed accordingly. Published studies’
data extraction included authors’ name, year of publi-
cation, countries of study implementation, study set-
ting, study period, study population, study design,
intervention, control, and outcome measures. Data
extraction from RCTs’ registered protocols included
Trial’s title, ClinicalTrials.gov identiﬁer, EudraCT
number, sponsor, sponsor protocol number, start
date and current status. For each included registered
RCT, we retrieved and reported on associated indexed
published papers.
We performed a descriptive analysis to report the
characteristics of included studies. A synthesis of the
studies’ ﬁndings was carried out and results summary
tables were produced on all considered outcomes.
Depending on studies’ heterogeneity, we planned to per-
form meta-analysis on pre-speciﬁed outcomes, including
efﬁcacy, immunogenicity, and safety outcomes.
RESULTS
Characteristics of included studies
We identiﬁed 227 records by running the pre-deﬁned
search strategies on the three selected databases. After
removing duplicates, 148 papers were assessed for eligi-
bility by title and abstract. Papers were screened and
selected as illustrated in Figure 1. Two papers were pub-
lished on 9vHPV clinical trials’ protocols, describing the
RCTs’ design and rationale but not reporting original
data; they were excluded from the review [32, 33]. Ten
papers met the inclusion criteria and were included in
the review.
Included papers’ characteristics are reported in
Table 1.
Included papers reported ﬁndings from eight differ-
ent clinical trials on 9vHPV’s efﬁcacy, immunogen-
icity, and/or safety. Of them, one paper reported
data on 9vHPV clinical efﬁcacy [34], 10 papers
reported data on 9vHPV immunogenicity [34–43],
and nine papers reported data on 9vHPV safety
[34–38, 40–43].
In particular:
. one paper reported the ﬁndings of the three Phase
II RCTs that were conducted to select the best
vaccine formulation to undergo Phase III evalu-
ation [38];
. one paper reported preliminary data on 9vHPV
clinical efﬁcacy in females aged 16–26 years, as
well as on 9vHPV immunogenicity and safety in
this population, compared with qHPV [34];
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. one paper reported data on 9vHPV immunogenicity
and safety in males aged 16–26 years, compared
with qHPV [41];
. one paper reported data on immunogenicity and
safety of 9vHPV in 9–15-year-old females, com-
pared with qHPV [43];
. two papers reported on 9vHPV bridging efﬁcacy to
9–15-year-old populations [42], 16–26-year-old het-
erosexual males and men having sex with men
(MSM) [35], respectively;
. one paper reported the ﬁndings of the Phase III trial
conducted to evaluate vaccines’ lot consistency [39];
. two papers reported data on concomitant adminis-
tration of 9vHPV with other vaccines, compared
with non-concomitant administration [37, 40];
. one paper reported data on 9vHPV immunogenicity
and safety in young females previously immunized
with qHPV vaccine [36].
The sections below, together with Tables 2–4,
report the synthesis of included RCTs’ ﬁndings, by
outcome. Meta-analysis of RCTs’ estimates could
not be performed due to studies’ heterogeneity in
terms of: study design, tested interventions, and com-
parisons, as well as targeted study populations.
Dose formulation data
Data from the Phase II dose formulation study were
published in June 2015 [38]. The paper reports the
ﬁndings of three RCTs conducted to compare
immunogenicity and safety of seven vaccine candi-
dates with licensed qHPV vaccine. The vaccine candi-
dates were: three dose formulations (low-, mid-, and
high-dose formulations) of an 8-valent HPV6/11/16/
18/31/45/52/58 vaccine (Study 1), three dose formula-
tions of a 9-valent HPV6/11/16/18/31/33/45/52/58
vaccine (Study 2), and qHPV vaccine concomitantly
administered with a 5-valent HPV31/33/45/52/58
(Study 3). All vaccines were administered on a
3-dose schedule at months 0, 2, and 6. Six-hundreds
and eighty, 1242 and 623 girls aged 16–26 years
were, respectively, randomized in the three studies.
Within each study, the primary immunogenicity
objective was to demonstrate that month 7 anti four
Fig. 1. PRISMA ﬂowchart of included published papers.
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Table 1. Characteristics of included published studies, reporting ﬁndings from randomized, controlled trial on 9vHPV
Reference
Trial’s NCT
number Study design Study site Study period
Study
population
Sample
size* Follow up Intervention Comparison Assessed outcomes Analysis
Joura et al.
[34]
NCT00543543 Phase III
Randomized,
double-blind
controlled trial
Multicenter
18
countries
September
2007–April
2013
Females,
16–26 years
14215 54 months 9vHPV (3 doses at
0, 2, and 6
months)
qHPV (3 doses at 0, 2,
and 6 months)
EFFICACY
IMMUNOGENICITY
SAFETY
Modiﬁed
intention-to-treat:
efﬁcacy
Per-protocol for
all assessed
outcomes
Luxembourg
et al. [38]
NCT00543543 Three Phase II
Randomized,
double-blind
controlled trials
(Study 1, Study
2, Study 3)
Multicenter
Study 1:3
countries
Study 2:7
countries
Sudy 3:5
countries
Study 1:
December
2005–
August 2007
Study 2:
September
2007–April
2013
Study 3:
October
2007–May
2009
Females,
16–26 years
Study 1:
680
Study 2:
1242
Sudy 3:
623
Study 1: 7
months
Study 2:
3 months
Study 3:
7 months
Study 1: 8vHPV
Study 2: 9vHPV
(low-, mid-, and
high-dose form.)
Sudy 3: qHPV +
5vHPV
Study 1, 2, and 3:
(3 doses at 0, 2,
and 6 months)
Study 1, 2, and 3:
qHPV (3 doses at 0,
2, and 6 months)
IMMUNOGENICITY
SAFETY
Per-protocol for all
assessed outcomes
Luxembourg
et al. [39]
NCT00943722 Phase III
Randomized,
double-blind
controlled trial
Multicenter
17
countries
(not reported) Females, 9–15
years
1935 7 months 9vHPV (3 doses at
0, 2, and 6
months)
9vHPV (3 doses at 0,
2, and 6 months)
IMMUNOGENICITY
(lot consistency study, 3
lots)
Per-protocol
Van Damme
et al. [42]
NCT00943722 Phase III
Randomized,
double-blind
controlled trial
Multicenter
17
countries
August 2009–
April 2013
Females,
16–26 years
females and
males 9–15
years
3074 7 months 9vHPV (3 doses at
0, 2, and 6
months) in
females, 16–26
years
9vHPV (3 doses at 0,
2, and 6 months) in
females and males
9–15 years
IMMUNOGENICITY
SAFETY (adult–
adolescent
immunobridging study)
ANTIBODY
PERSISTANCE
Per-protocol for all
assessed outcomes
Schilling et al.
[40]
NCT00988884 Randomized,
double-blind
controlled trial
Multicenter
4 countries
October
2009–
February
2011
Males and
females,
11–15 years
1241 8 months 9vHPV (3 doses at
0, 2, and 6
months) +
concomitant
MCV4/Tdap (1
dose at 0 month)
9vHPV (3 doses at 0,
2, and 6 months) +
non-concomitant
MCV4/Tdap (1 dose
at 1 month)
IMMUNOGENICITY
SAFETY
Per-protocol for all
assessed outcomes
Garland et al.
[36]
NCT01047345 Randomized,
double-blind
controlled trial
Multicenter
8 countries
February
2010–June
2011
Females, 12–
26 years who
previously
received a
qHPV
three-dose
regimen
924 7 months 9vHPV (3 doses at
0, 2, and 6
months)
Placebo IMMUNOGENICITY
SAFETY
Per-protocol for all
assessed outcomes
Kosalaraksa
et al. [37]
NCT01073293 Randomized,
double-blind
controlled trial
Multicenter
6 countries
April 2010–
June 2011
Males and
females,
11–15 years
1054 8 months 9vHPV (3 doses at
0, 2, and 6
months) +
concomitant
Tdap-IPV (1
dose at 0 month)
9vHPV (3 doses at 0,
2, and 6 months) +
non-concomitant
Tdap-IPV (1 dose at
1 month)
IMMUNOGENICITY
SAFETY
Per-protocol for all
assessed outcomes
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original vaccine HPV types (anti-HPV6/11/16/18) geo-
metric mean titers (GMTs) were non-inferior in sub-
jects who received experimental vaccines compared
with subjects in the control group. Non-inferiority
was deﬁned as the lower bound of the two-sided
95% CI of the GMT ratio (experimental arm/control
arm) being >0·5 for each of anti-HPV types 6/11/16/
18. Among all vaccine candidates, the 9vHPV mid-
dose formulation containing 30/40/60/40/20/20/20/20/
20 mg of HPV6/11/16/18/31/33/45/52/58 virus such as
particles, and 500 mg of amorphous aluminum
hydroxyl-phosphate sulfate adjuvant was selected for
all subsequent Phase III efﬁcacy, immunogenicity,
and safety evaluations.
Successful 9vHPV vaccine candidate was reported
to: (i) provide non-inferior antibody responses com-
pared with qHPV vaccine with respect to the four
HPV types covered by both vaccines (the lower
bound 95% CI GMT ratio exceeded 0·5 for all HPV
types), (ii) be strongly immunogenic against ﬁve add-
itional oncogenic HPV types (>95% subjects serocon-
verted at month 3), and (iii) be generally well
tolerated. Injection-site adverse events (AEs) were
slightly higher in the selected 9vHPV vaccine as com-
pared with qHPV (92·4% vs. 90·3%).
Efﬁcacy
The 9vHPV efﬁcacy ﬁndings of included studies are
summarized in Table 2. One paper has been published
on 9vHPV clinical efﬁcacy so far [34]. It reports pre-
liminary data of a Phase III multinational multicenter
efﬁcacy study conducted on 14 215 women aged 16–26
years comparing 9vHPV to qHPV. The primary
efﬁcacy outcome was the combined incidence of sev-
eral conditions related to 9vHPV additional HPV
types (HPV-31, 33, 45, 52, 58) – with follow-up over
a 54-month period. Analysis in the modiﬁed
intention-to-treat population (which included subjects
both not HPV-infected and HPV-infected at the time
of vaccination, who received at least one dose of vac-
cine and for whom there was at least one measurement
of efﬁcacy) showed high-grade cervical, vulva, and
vaginal disease incidence to be the same in the
9vHPV and qHPV arms, irrespective of HPV testing
results (14·0 per 1000 persons-years, risk reduction =
0·7, 95% CI −15·7 to 14·8), while when restricting
the analysis to not HPV-infected participants at the
time of vaccination, 9vHPV risk reduction was
42·5%; (95% CI 7·9–65·9), this reaching 100% (95%
CI 70·4–100) when only considering disease relatedT
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Table 2. HPV 9-valent vaccine clinical efﬁcacy and bridging efﬁcacy ﬁndings of included studies
Subgroup
Efﬁcacy comparison with qHPV vaccine risk reduction, (95% CI)
Females, 16–26 years [34]
High-grade cervical,
vulvar, and vaginal
disease
High-grade cervical epithelial neoplasia,
adenocarcinoma in situ, and cervical cancer
Persistent infection 56
months’ duration
Related to HPV-31, 33,
45, 52, or 58
96·7 (80·9–99·8) 96·3 (79·5–99·8) 96·0 (94·4–97·2)
Related to HPV-6, 11,
16, or 18
66·6 (−203·0 to 98·7) −0·4 (4−999 to 97·4) 26·4 (−4·3 to 47·5)
All participants 0·7 (−15·7 to 14·8)* −0·3 (−17·3 to 14·3)*
HPV uninfected on day 1 42·5 (7·9–65·9)* 39·7 (1·8–64·3)*
Not related to 9
vaccine HPV types
19·7 (−34·5 to 52·5)* 14·3 (−49·1 to 49·1)*
Related to 9 vaccine
HPV types
100 (70·4–100)* 100 (70·3–100)*
HPV infected on day 1 −4·8 (−23·3 to 10·8)* −5·3 (−24·1 to 10·8)*
Not related to 9
vaccine HPV types
−2·0 (−30·0 to 19·9)* 1·8 (−26·0 to 23·5)*
Related to 9 vaccine
HPV types
−6·8 (−33·2 to 14·3)* −11·3 (−39·6 to 11·0)*
Bridging efﬁcacy comparison with 9vHPV administered to females, 16–26 years
Month 7 GMT ratio (95% CI)
Females, 9–15 years [42] Males, 9–15 years [42] Heterosexual males,
16–26 years [35]
MSM, 16–26 years [35]
Anti-HPV-6 1·90 (1·70–2·14) 2·31 (2·07–2·59) 1·11 (1·02–1·21) 0·81 (0·70–0·93)
Anti-HPV-11 1·83 (1·63–2·06) 2·10 (1·88–2·36) 1·09 (1·00–1·19) 0·77 (0·67–0·89)
Anti-HPV-16 1·98 (1·77–2·22) 2·45 (2·19–2·74) 1·20 (1·10–1·30) 0·82 (0·72–0·94)
Anti-HPV-18 2·44 (2·13–2·80) 3·20 (2·80–3·65) 1·19 (1·08–1·31) 0·89 (0·77–1·04)
Anti-HPV-31 2·51 (2·21–2·85) 2·95 (2·60–3·34) 1·24 (1·13–1·37) 0·74 (0·64–0·86)
Anti-HPV-33 2·10 (1·87–2·36) 2·57 (2·29–2·88) 1·19 (1·10–1·30) 0·78 (0·69–0·89)
Anti-HPV-45 2·62 (2·27–3·03) 3·33 (2·89–3·84) 1·27 (1·14–1·41) 0·85 (0·72–0·99)
Anti-HPV-52 2·22 (1·97–2·51) 2·47 (2·19–2·79) 1·15 (1·05–1·26) 0·70 (0·61–0·80)
Anti-HPV-58 2·18 (1·93–2·45) 2·66 (2·37–2·98) 1·25 (1·14–1·36) 0·78 (0·68–0·89)
Month 7 seroconversion % difference (95% CI)
Females, 9–15 years [42] Males, 9–15 years [42] Heterosexual males, 16–26 years [35]
Anti-HPV-6 0·1 (−0·8 to 1·5) 0·1 (−0·7 to 1·5) 0·1 (−0·7 to 0·9)
Anti-HPV-11 0 (−0·7 to 1·2) 0 (−0·7 to 1·2) 0·1 (−0·3 to 0·8)
Anti-HPV-16 0 (−0·7 to 1·2) 0 (−0·7 to 1·2) 0·1 (−0·3 to 0·7)
Anti-HPV-18 0·1 (−0·8 to 1·5) 0·3 (−0·4 to 1·6) 0·1 (−0·4 to 0·8)
Anti-HPV-31 0·3 (−0·4 to 1·7) 0·3 (−0·4 to 1·7) 0 (−0·4 to 0·5)
Anti-HPV-33 0·3 (−0·4 to 1·6) 0·3 (−0·4 to 1·6) 0·1 (−0·3 to 0·7)
Anti-HPV-45 0·4 (−0·6 to 1·8) 0·5 (−0·1 to 2·0) 0·2 (−0·4 to 1·0)
Anti-HPV-52 0·3 (−0·4 to 1·7) 0·3 (−0·4 to 1·7) 0·2 (−0·2 to 0·9)
Anti-HPV-58 0 (−0·7 to 1·2) 0 (−0·7 to 1·2) 0·2 (−0·2 to 0·9)
MSM, men-having-sex with men; 9vHPV, human papillomavirus 9-valent vaccine; qHPV, HPV quadrivalent vaccine; GMT,
geometric mean titer.
* Intention-to-treat populations (all other estimates are on per protocol populations).
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to 9vHPV HPV types. Analysis conducted on the per-
protocol population (subjects who received all three
doses of vaccine within 1 year, who were seronegative
on day 1 and PCR-negative from day 1 through
month 7 and had no protocol violations) reported
9vHPv vaccine efﬁcacy to be 96% or above for all con-
sidered clinical outcomes related to HPV types 31, 33,
45, 52, or 58 as well as persistent infection (56
months’ duration, Table 2) [34].
Two published immunobridging efﬁcacy studies
inferred 9vHPV efﬁcacy in males and females aged
9–15 years [42], in heterosexual males and in MSM
aged 16–26 years [35], comparing immunogenicity
data between individuals in the intervention arms
and 16–26-year-old female controls. By deﬁnition,
bridging studies generate immunogenicity data to sup-
port the extrapolation of data on efﬁcacy or safety
obtained under speciﬁc circumstances of use (in our
case 9vHPV efﬁcacy in 16–26-year-old females) to
other situations (e.g. different age groups or different
populations) [44]. Both studies reported month 7
GMTs in the intervention arms to be non-inferior
(lower bound of the two-sided 95% CI of the GMT
ratio >0·67) to the control arm for all 9vHPV vaccine
types, as well as seroconversion non-inferiority in
more than 99% of study participants (deﬁned as the
lower bound of the two-sided 95% CI for the differ-
ences in seroconversion rates being >−5 percentage
points for each 9vHPV HPV type) (Table 2). Data
on 9vHPV immunogenicity MSM aged 16–26 years
showed lower antibody response compared with het-
erosexual males for all tested HPV types (GMT ratios
MSM/women for all 9vHPV vaccine types are
reported in Table 2) [35].
Immunogenicity
All included articles assessed 9vHPV immunogenicity.
The majority of studies adopted a non-inferiority
design. Immunogenicity outcomes included interven-
tion–control comparisons of month 7 GMTs for
anti-HPV types and proportion of studies’ partici-
pants with seroconversion to the 9vHPV vaccine
types at 4 weeks after the administration of the third
vaccine dose (month 7).
The immunogenicity analyses ﬁndings of the dose-
formulation Phase II study has been described in the
previous section [38] and reference was previously
made to the published lot-consistency study – con-
ducted to meet regulatory requirements – that
reported three different lots of 9vHPV to elicit equiva-
lent antibody response and seroconversion rates [39].
In addition, data are available on: (i) 9vHPV vs.
qHPV immunogenicity [34, 41, 43]; (ii) 9vHPV
immunogenicity in females aged 16–26-years old vs.
other age and gender populations to infer bridging
efﬁcacy [35, 42]; (iii) 9vHPV immunogenicity when
co-administrated with other vaccines (including men-
ingococcal, tetanus, diphtheria, pertussis, polio vac-
cines) [37, 40]; and (iv) 9vHPV immunogenicity in
subjects previously vaccinated with qHPV [36].
Three studies reported immunogenicity data com-
paring 9vHPV to qHPV in females aged 16–26 years
[34], in females aged 9–15 years [43] and in males
Table 3. HPV 9-valent vaccine immunogenicity ﬁndings of included studies
Study population Analysis HPV type
Immunogenicity comparison with qHPV vaccine
Month 7 GMT ratio Month 7 seroconversion % difference
Females, 16–26 years [34]* Per-protocol Anti-HPV-6 1·02 (0·99–1·06) 0·0 (−0·3 to 0·2)
Anti-HPV-11 0·80 (0·77–0·83) 0·0 (−0·1 to 0·2)
Anti-HPV-16 0·99 (0·96–1·03) 0·0 (−0·1 to 0·2)
Anti-HPV-18 1·19 (1·14–1·23) 0·1 (−0·1 to 0·4)
Females, 9–15 years [43] Anti-HPV-6 1·07 (0·93–1·23)
Anti-HPV-11 0·93 (0·80–1·08)
Anti-HPV-16 0·97 (0·85–1·11)*
Anti-HPV-18 1·08 (0·91–1·29)*
Males, 16–26 years [41]* Per-protocol Anti-HPV-6 1·23 (1·04–1·45) −0·5 (−0·6 to 0·2)
Anti-HPV-11 0·89 (0·76–1·04) 0·0 (0–0)
Anti-HPV-16 1·04 (0·89–1·21) 0·0 (−0·1 to 0)
Anti-HPV-18 1·12 (0·91–1·37) 0·0 (−0·1 to 0)
qHPV, human papillomavirus quadrivalent vaccine; GMT, geometric mean titer.
* The P value for non-inferiority was <0·001 for all comparisons HPV 9-valent vaccine vs. qHPV vaccine.
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Table 4. The 9vHPV safety ﬁndings of included studies; adverse events (AEs, %)
Event
Comparison: 9vHPV vs. qHPV
Females, 16–26 years [34] Females, 9–15 years [43]* Males, 16–26 years [41]*
9vHPV qHPV 9vHPV qHPV 9vHPV qHPV
One or more AEs 93·9% 90·7% 96·0% 93·7% 82·3% 81·9%
Injection-site events 90·7% 84·9% 91·6% 88·3% 79·0% 72·2%
Systemic events 55·8% 54·9% 47·5% 52% 40·7% 40·3%
Serious events 3·3% 2·6% 0·3% 0·7% 0·0% 0·0%
Discontinuation due to AEs 0·1% 0·1% 0·3% 0·3% 0·0% 0·0%
Comparison: 9vHPV in Females, 16–26 years vs. other groups
Females, 16–26 years [42] Females, 9–15 years [42] Males, 9–15 years [42] Females, 16–26 years [35] Males, 16–26 years [35]
One or more AEs 90·01% 86·6% 81·0% 89·4% 76·2%
Injection-site events 85·4% 81·9% 72·8% 84·1% 67·6%
Systemic events 57·1 45·0% 41·8% 37·1% 48·8%
Serious events 3·2% 0·9% 1·7% 2·4% 1·6%
Discontinuation due to AEs 0·0% 0·0% 0·2% 0·3% 0·1%
Comparison: 9vHPV vs. placebo in females, 12–26 years, previously vaccinated with qHPV [36]
9vHPV Placebo
One or more AEs 95·9% 75·1%
Injection-site events 91·9% 43·9%
Systemic events 59·7% 55·7%
Serious events 0·5% 1·0%
Discontinuation due to AEs 0·5% 0·0%
Comparison: concomitant vs. non-concomitant 9vHPV administration with other vaccines
Post-vaccination 1 [40] Post-vaccination 2 [40] Post-vaccination 3 [40]
Concomitant Non-concomitant Concomitant Non-concomitant Concomitant Non-concomitant
One or more AEs 85·3% 85·1% 51·9% 50·4% 55·4% 52·8%
Injection-site events 80·9% 80·4% 46·7% 46·5% 52·1% 48·4%
Systemic events 43·1% 42·4% 16·1% 15·0% 14·8% 16·2%
Serious events 0·2% 0·2% 0·2% 0·0% 0·0% 0·0%
Discontinuation due to AEs 0·0% 0·2% 0·2% 0·0% 0·0% 0·0%
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aged 16–26 years [41]. These are summarized in
Table 3. They showed: (i) 9vHPV non-inferiority as
compared with qHPV with regard to HPV types 6,
11, 16, and 18 in females and males aged 16–26
years (GMT ratios ranging from 0·80 and 1·19 and
from 0·89 and 1·23, respectively, Table 3) [34, 41];
(ii) 9vHPV non-inferiority as compared with qHPV
with regard to HPV types 16 and 18 in females aged
9–15 years [43]; and (iii) virtually all studies’ partici-
pants seroconversion for HPV 31/33/45/52/58 at
month 7 (in females aged 9–15 years and 16–26
years and in males aged 16–26 years [34, 41, 43];
Table 3).
Two studies have been published on concomitant
administration of 9vHPV with other vaccines, such
as meningococcal (MCV4), tetanus, diphtheria, per-
tussis (Tdap) and polio vaccines, reporting non-
inferior immune response in subjects receiving
9vHPV concomitantly with other vaccines as com-
pared with non-concomitant administration [37, 40].
In particular, authors reported concomitant adminis-
tration of 9vHPV together with MCV4 and Tdap to
elicit non-inferior GMTs and seroconversion rates
for all 9vHPV antigens as well as non-inferior immune
response and seroconversion to MCV4 and Tdap vac-
cines’ components as compared with non-concomitant
vaccines’ administration in subjects aged 11–15-years
old [40]. Similarly, ﬁndings from another RCT
showed all 9vHPV HPV types 7 month GMTs and
seroconversion non-inferiority in the concomitant
group compared with the non-concomitant group.
Non-inferiority of immune response was established
for diphtheria, tetanus, all pertussis, and polio anti-
gens for both groups [37].
One study has been published reporting ﬁndings
from an RCT that assessed 9vHPV immunogenicity
vs. placebo in females aged 12–26, previously vacci-
nated with qHPV [36]. Seroconversion at month 7
was reported to be >98% for all 9vHPV HPV types,
with marked elevations in GMTs. Data from cross-
study analysis showed anti-HPV 31/33/45/52/58
GMTs to be lower than in study subjects administered
9vHPV vaccine who had not previously received
qHPV vaccine [36].
Safety
Nine papers reported data on 9vHPV vaccine safety;
of them, one is the Phase II RCTs conducted to select
the right 9vHPV formulation [38], three made com-
parisons between 9vHPV and qHPV vaccine [34, 41,T
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43], two made comparisons between 9vHPV adminis-
tered in different age and gender populations (immu-
nobridging studies) [35, 42], two assessed 9vHPV
safety comparing concomitant and non-concomitant
administration with other vaccines [37, 40] and one
assessed 9vHPV safety against placebo in girls previ-
ously vaccinated with qHPV vaccine [36]. In ﬁve stud-
ies, participants recorded injection-site events (AE,
within 5 days after vaccination) and systemic events
(within 15 days after vaccination) on VRCs (vaccin-
ation report cards) [34, 35, 38, 41, 42]. Injection-site
AEs were rated by study subjects to be mild/moder-
ate/severe. AEs causality was assessed by investigators
and classiﬁed as possibly, probably, or deﬁnitely vac-
cine related. Serious AEs were pre-deﬁned as any AE
resulting in deaths or in which discontinuation due to
AEs was reported. AEs were summarized as frequen-
cies and percentages by study arm and AE type. The
9vHPV safety ﬁndings are reported in Table 4.
Overall, 9vHPV vaccine recipients were more likely
than qHPV vaccine recipients to have AEs related to
the injection site (90·7% vs. 84·9% in females aged
16–26) [34], while systemic AEs distribution was simi-
lar between intervention and control groups (55·8% vs.
54·9% in female aged 16–26) [34]. Discontinuation
rates because of vaccine-related AE were rare and all
but one study [34] reported no vaccine-related serious
AEs [34, 38, 41, 43]. In immunobridging studies
injection-site or systemic AEs were lower in heterosex-
ual men and MSM aged 16–26 and in males and
females aged 9–15 years as compared with controls
(females aged 16–26 years) [35, 42]. In studies asses-
sing concomitant vaccines administration, injection-
site AEs of swelling after 9vHPV and Tdap-IPV
were more frequent in concomitant administration
arms as compared with non-concomitant ones (after
9vHPV: 14·4% vs. 9·4% [40], after Tdap-IPV 21·7%
vs. 31·3% [37]); the risk difference between the groups
being statistically signiﬁcant. No other statistically
signiﬁcant differences were reported in terms of AEs
after all vaccines’ administration between study arms
[37, 40]. In both studies, few subjects discontinued
because of an AE and no deaths were reported [37,
40]. In the placebo-controlled trial conducted in
females who previously received qHPV, injection-site
AEs were more frequent in the intervention arm
(91·1% vs. 43·9) and increased with subsequent
9vHPV vaccine doses, the incidence of serious
vaccine-related AEs and discontinuation was reported
to be low and no subjects died during the study [36].
Ongoing clinical studies
One hundred and forty records were initially retrieved
searching the selected clinical trials’ registries and plat-
forms (Fig. 2). After removing duplicates, 87 RCTs
were excluded as they did not include 9vHPV adminis-
tration in the intervention or control study arms.
Twenty-four relevant clinical trial protocols met the
inclusion criteria, referring to 16 clinical trials conducted
on the 9vHPV vaccine (some RCTs were registered
more than once in different RCT registries; Table 5).
As of August 25, 2016, 16 Phase II or Phase III
multicenter multinational RCTs have been conducted
on 9vHPV, the ﬁrst of which was started in February
2007 [45] while the last was started in August 2016
[46]. Thirteen (81·2%) RCTs are directly sponsored
by pharmaceutical companies, two are sponsored by
universities [46, 47], one by the US National Cancer
Institute [48] and one by the Danish Department of
Infectious Diseases [49].
Of the 16 identiﬁed RCTs, eight (50%) have been
completed, three (18·8%) are active but not recruiting
[50–52], four (25%) are ongoing or recruiting [47–49,
53], and one (6·3%) is not recruiting participants yet [46].
For eight RCTs (50%) results or preliminary results
have been published in scientiﬁc peer-reviewed jour-
nals (Tables 1–4, results described in previous sec-
tions); one completed RCTs does not have published
studies [54].
Of the active RCTs, three are assessing immunogen-
icity and tolerability of less than three-dose 9vHPV
vaccine schedules [46, 47, 51]. The ﬁrst one – started
in December 2013 and no longer anymore – is a
37-month safety and immunogenicity study conducted
with the aim of assessing whether investigational two-
dose regimens (0, 6 months and 0, 12 months) adminis-
tered in males and females aged 9–14 years elicit non-
inferior immunogenicity and safety proﬁles as com-
pared with three-dose regimens administered to females
aged 16–26 [51]. The second one – started in September
2015, and still recruiting – aims to assess immunogen-
icity of 9vHPV and bHPV vaccines administered to
males and females aged 9–10 years, according to a 0–
6 month schedule to infer possible interchangeable
use of the two vaccines [47]. The third one – about to
start recruiting females aged 9–14 years in Tanzania –
will compare immunogenicity between one-dose and
two-dose 9vHPV and bHPV vaccines and three-dose
regimens of both vaccines [46].
One active RCT is a long-term follow-up study of
the ﬁrst 9vHPV vaccine RCT (NCT00543543),
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currently being conducted in countries with centra-
lized cervical cancer screening infrastructures
(Denmark, Norway, and Sweden) that aims to evalu-
ate the long-term effectiveness, immunogenicity, and
safety of 9vHPV vaccine in females aged 16–26
years [52].
Within ongoing European RCTs, one efﬁcacy
immunobridging study started in July 2016 and cur-
rently recruiting subjects in four European countries
aims at assessing immunogenicity and tolerability of
the 9vHPV vaccine in females aged 27–45 years com-
pared with females aged 16–26 years [53]. Another
RCT – currently recruiting subjects in Denmark –
aims at inferring 9vHPV vaccine efﬁcacy in
HIV-infected sexually active MSM, measuring
changes in the prevalence of HPV types in either
anus, oral cavity, or penis as well as well as antibody
response [49].
One Phase IIA RCT started in March 2016 aims at
assessing immunogenicity of a prime and deferred-
booster dosing 9vHPV vaccine schedule among
females aged 9–11 years [48]. Primary and secondary
objectives are to determine persistence and stability
of the immune response to HPV types 16/18 and
HPV types 6/11/31/33/45/52/58, respectively, between
6, 12, 18, and 24 months after the prime dose and
prior to the administration of the second dose [48].
DISCUSSION
We systematically retrieved and comprehensively sum-
marized all the available published evidence on
9vHPV efﬁcacy, immunogenicity, and safety derived
from RCTs, as well as systematically presented an
update of the ongoing research on the topic.
To date, 10 papers have been published reporting
results or preliminary results from RCTs on 9vHPV,
of which nine papers reported results from clinical
studies included in 9vHPV clinical development pro-
gram. Overall, there are 16 registered RCTs on
9vHPV, of which eight are currently active or
ongoing.
The 9vHPV clinical efﬁcacy has been directly
assessed on females aged 16–26 years in one study
that reported 96·7% 9vHPV vaccine efﬁcacy against
composite high-grade cervical, vulvar, or vaginal dis-
ease related to HPV types 31, 33, 45, 52, and 58 [34].
Efﬁcacy against HPV types 6, 11, 16, and 18 was
inferred through a non-inferiority approach that
demonstrated 9vHPV non-inferior immunogenicity
Fig. 2. PRISMA ﬂowchart of included registered trials (update August 25, 2016).
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Table 5. Existing randomized controlled trials on human papillomavirus 9-valent vaccine
Title
Clinical trials.
gov identiﬁer EudraCT number
Sponsor & sponsor
protocol number Start date Status
Published
results
A Randomized, International, Double-Blinded
(With In-House Blinding), Controlled With
GARDASIL, Dose-Ranging, Tolerability,
Immunogenicity, and Efﬁcacy Study of a
Multivalent Human Papillomavirus (HPV) L1
Virus-Like Particle (VLP) Vaccine Administered
to 16- to 26- Year-Old Women
NCT00543543 EUCTR2007-003528-39-DK/
SE/DE/AT
Merck Sharp & Dohme
Corp.
V503‐001
September
2007
Completed* Yes [34, 38]
A Phase III Clinical Trial to Study the
Immunogenicity, Tolerability, and
Manufacturing Consistency of V503 (A
Multivalent Human Papillomavirus [HPV] L1
Virus-Like Particle [VLP] Vaccine) in
Preadolescents and Adolescents (9 to 15 Year
Olds) With a Comparison to Young Women (16
to 26 Year Olds)
NCT00943722 EUCTR2009-011617-25-FI/BE/
AT/SE/ES
Merck Sharp & Dohme
Corp.
V503‐002
August
2009
Active, not
recruiting*
Yes [39, 42]
A Phase III Clinical Trial to Study the Tolerability
and Immunogenicity of 9vHPV (V503), a
Multivalent Human Papillomavirus (HPV) L1
Virus-Like Particle (VLP) Vaccine, in 16- to
26-Year-OldMen and 16- to 26-Year-OldWomen
NCT01651949 EUCTR2012-002758-22-DE/ES/
FI/SE/DK
Merck Sharp & Dohme
Corp.
V503‐003
October
2012
Completed* Yes [35]
An Open-Label Phase III Clinical Trial to Study
the Immunogenicity and Tolerability of
GARDASIL®9 (A Multivalent Human
Papillomavirus [HPV] L1 Virus-Like Particle
[VLP] Vaccine) in Adult Women (27- to
45-Year-Olds) Compared to Young Adult
Women (16-to-26 Year-Olds)
– EUCTR2015-005093-38-DE/
AT/ES/BE
Sanoﬁ Pasteur MSD
GDS02C/V503-004
July 2016 Ongoing† No
A Phase III Open-Label Clinical Trial to Study the
Immunogenicity and Tolerability of V503 (A
Multivalent Human Papillomavirus [HPV] L1
Virus-Like Particle [VLP] Vaccine) Given
Concomitantly With Menactra™ and Adacel™ in
Preadolescents and Adolescents (11 to 15 Year
Olds)
NCT00988884 – Merck Sharp & Dohme
Corp.
V503‐005
October
2009
Completed* Yes [40]
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Table 5 (cont.)
Title
Clinical trials.
gov identiﬁer EudraCT number
Sponsor & sponsor
protocol number Start date Status
Published
results
A Phase III, Randomized, International,
Placebo-Controlled, Double-Blind Clinical Trial
to Study the Tolerability and Immunogenicity of
V503, a Multivalent Human Papillomavirus
(HPV) L1 Virus-Like Particle (VLP) Vaccine,
Given to Females 12–26 Years of Age Who Have
Previously Received GARDASIL™
NCT01047345 EUCTR2009-015500-26-SE/DK Merck Sharp & Dohme
Corp.
V503‐006
February
2010
Completed* Yes [36]
A Phase III Open-Label Clinical Trial to Study the
Immunogenicity and Tolerability of V503, a
Multivalent Human Papillomavirus (HPV) L1
Virus-Like Particle (VLP) Vaccine, Given
Concomitantly With REPEVAX™ in
Preadolescents and Adolescents (11 to 15 Year
Olds)
NCT01073293 EUCTR2009-016218-26-FI/DE/
BE/AT/DK
Merck Sharp & Dohme
Corp.
V503‐007
April 2010 Completed* Yes [37]
A Phase III Open-label, Safety, Tolerability and
Immunogenicity Study of a 9-Valent Human
Papillomavirus (HPV) L1 Virus-Like Particle
(VLP) Vaccine Administered to 9- to 15-Year-Old
Japanese Preadolescent and Adolescent Girls
NCT01254643 – Merck Sharp & Dohme
Corp.
V503‐008
January
2011
Completed* No
A Randomized, Double-Blinded, Controlled With
GARDASIL (Human Papillomavirus Vaccine
[Types 6, 11, 16, 18] (Recombinant, Adsorbed)),
Phase III Clinical Trial to Study the
Immunogenicity and Tolerability of V503
(9-Valent Human Papillomavirus (HPV) Vaccine)
in Preadolescent and Adolescent Girls (9- to
15-year-old)
NCT01304498 EUCTR2010-023393-39-FI/BE
/SE/ES/DK/IT
Sanoﬁ Pasteur MSD
V503‐009
GDS01C
February
2011
Completed* Yes [43]
A Phase III Clinical Trial to Study the Tolerability
and Immunogenicity of a 2-dose Regimen of
V503, a Multivalent Human Papillomavirus
(HPV) L1 Virus-Like Particle (VLP) Vaccine,
Administered in Preadolescents and Adolescents
(9 to 14 Year Olds) With a Comparison to Young
Women (16 to 26 Year Olds)
NCT01984697 EUCTR2013-001314-15-CZ/
NO/DK/ES
Merck Sharp & Dohme
Corp.
V503‐010
December
2013
Active, not
recruiting*
No
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Table 5 (cont.)
Title
Clinical trials.
gov identiﬁer EudraCT number
Sponsor & sponsor
protocol number Start date Status
Published
results
A Randomized, Double-Blinded, Controlled With
GARDASIL (Human Papillomavi–us Vaccine
[HPV] [Types 6, 11, 16, 18] (Recombinant,
Adsorbed)), Phase 3 Clinical Trial to Study the
Immunogenicity and Tolerability of V503
(9-Valent Human Papillomavirus L1 Virus-Like
Particle [VLP] Vaccine) in 16- to 26-year-old Men
NCT02114385 EUCTR2013-003399-10-DE/
BE/NL
Sanoﬁ Pasteur MSD
V503‐020
March 2014 Completed* Yes [41]
A Registry-Based Extension of Protocol V503-001
in Countries With Centralized Cervical Cancer
Screening Infrastructures to Evaluate the
Long-Term Effectiveness, Immunogenicity, and
Safety of Multivalent Human Papillomavirus
(HPV) L1 Virus- Like Particle (VLP) Vaccine as
Administered to 16- to 26- Year- Old Women
NCT02653118 Merck Sharp & Dohme
Corp.
V503‐021
January
2016
Active, not
recruiting*
No
Immunogenicity and Safety of Gardasil-9 and
Cervarix When Administered to 9–10-year-old
Subjects According to 0–6 Month Schedule
NCT02567955 – Laval University
HPV 2355
September
2015
Recruiting* No
A Prospective, Single-Arm, Open-Label,
Non-randomized, Phase IIA Trial of a
Nonavalent Prophylactic HPV Vaccine to Assess
Immunogenicity of a Prime and Deferred-Booster
Dosing Schedule Among 9–11 Year-Old Girls
NCT02568566 National Cancer
Institute (NCI)
NCI-2015-01645
March 2016 Recruiting* No
Efﬁcacy of nonavalent vaccine against human
papilloma virus (HPV) in HIV infected sexually
active men who have sex with men (MSM)
– EUCTR2015-004524-65-DK Department of
Infectious Diseases
Inf.Q002
November
2015
Ongoing† No
A Dose Reduction Immunobridging and Safety
Study of Two HPV Vaccines in Tanzanian Girls
NCT02834637 London School of
Hygiene and Tropical
Medicine
MITU-002
August
2016
Not yet
recruiting
No
* As reported by ClinicalTrials.gov.
†As reported by European Union Clinical Trials Register.
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compared with qHPV. Non-inferiority study design
represents the primary tool to demonstrate that a
new or reformulated vaccine, or a new regimen of
already licensed products, is equivalent to the existing
vaccine or current vaccine schedule [55, 56].
Although it is well known that HPV vaccine
efﬁcacy is highest in HPV infection naïve populations
and that young age groups are therefore the target
group for prophylactic HPV vaccination, 9vHPV clin-
ical efﬁcacy is not directly tested on these populations
due to low exposure to HPV but, instead, inferred
extending older subjects efﬁcacy data to younger
populations (immunobridging efﬁcacy). In fact,
adult-to-adolescent, as well as female-to-male pub-
lished immunobridging studies have allowed inference
of 9vHPV efﬁcacy in males and females aged 9–15
years and in males aged 16–26 years. Overall,
9vHPV has been proven to be safe and well tolerated
in both females and males in different age groups,
with AE proﬁles similar to that of the qHPV vaccine.
Other RCTs, including currently ongoing ones,
address other aspects relevant to the 9vHPV vaccine,
including: vaccine co-administration with other vac-
cines; administration in subjects that previously
received qHPV; and 9vHPV efﬁcacy in less than three-
dose regimens.
Evidence from completed RCTs has been used to
support marketing authorization applications and to
inform National Immunization Technical Advisory
Groups (NITAGs). After the FDA licensed 9vHPV
for use in females aged 9–26 years and in males aged
9–15 years in 2014, it extended its indication to include
use in males aged 16–26 years in December 2015. In
February 2015, ACIP recommended 9vHPV as one
of three HPV vaccines to be used for routine vaccin-
ation at age 11 or 12 years as well as for females
aged 13–26 and males aged 13–21 years not previously
vaccinated. Vaccination is also recommended through
age 26 years for MSM and for immunocompromised
subjects [23]. Medical and scientiﬁc associations are
progressively including the 9vHPV immunization in
their recommendations [57–60].
As scientiﬁc evidence is accumulating on the
9vHPV vaccine from clinical trials and from other
study designs, and as immunization recommendations
are built and constantly updated on the basis of their
ﬁndings, several crucial aspects are to be taken into
consideration when trying to forecast the public health
impact of universal 9vHPV immunization – to begin
with, the broadened protection associated with the
ﬁve additional HPV types contained in the 9vHPV
vaccine. Although some evidence is available on
bHPV and qHPV vaccine cross-protection [61], there
is no doubt that extending direct protection to ﬁve
additional HPV types offers great potential. In fact,
in the USA, 10% of invasive HPV-associated cancers
(14% for females; 4% for males), 15% of cervical can-
cers, and 25% of 5CIN2 are attributable to the ﬁve
additional types contained in the 9vHPV [62–64].
Although accurate global estimates are missing, a
large amount of data is available on HPV genotype-
speciﬁc prevalence of cervical cancers and other
HPV-related cancers in different settings and study
populations [16, 65–70]. This has allowed estimation
that 9vHPV vaccine use might expand overall protec-
tion against cervical cancer to over 90% [70, 71], and –
in general – signiﬁcantly reduce the burden of
HPV-related disease [29, 72–75].
For broader roll-out of the 9vHPV vaccine a number
of other clinical and organizational aspects are to be
considered and are currently being assessed by ongoing
research. For instance, long-term follow-up data on
9vHPV efﬁcacy are not yet available. The longest
follow-up trial data for bHPV and qHPV vaccines
showed them to protect against infection for at least 5
[76] and 9·4 [77] years, respectively. Currently, the long-
est available follow-up data on 9vHPV reports >90%
of vaccinated males and females aged 9–15 to remain
seropositive through 2·5 years after third vaccination
[42]. In the future, an extension of the ﬁrst 9vHPV
efﬁcacy trial, currently ongoing in three Scandinavian
countries with an efﬁcient centralized cancer screening
program with the aim of monitoring long-term safety,
effectiveness, and immunogenicity of 9vHPV, will
allow inference of information on duration of effect
as well as to track viral-type replacement [52].
Furthermore, the National Cancer Institute is currently
running an RCT which will provide evidence on
immunogenicity of a prime and deferred-booster dos-
ing schedule among young girls [48].
The number of doses contained in a 9vHPV regi-
men is another relevant aspect on which research is
currently ongoing and whose ﬁndings are likely to
impact immunization effectiveness. In fact, there is a
general interest in simpliﬁed HPV vaccine schedules,
which reduce required resources, facilitate immuniza-
tion programs’ implementation and might increase
vaccine acceptability and uptake. In Europe, as well
as in other countries, two-dose bHPV and qHPV vac-
cine schedules have been approved for subjects aged
9–14 and 9–13 years, respectively, based on non-
inferiority immunogenicity data. Since 2014, WHO
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has recommended two-dose regimens for subjects
younger than 15. With regards to 9vHPV, research
on less than three-dose regimens’ efﬁcacy is ongoing
and promising preliminary results from one active
RCT were presented to ACIP in February 2016 [51,
78]. The study’s ﬁndings report two-dose regimens in
males and females aged 9–14 to elicit no inferior
immunogenicity and a safety proﬁle comparable
with the standard three-dose regimen in older females
[51]. Other dose reduction immunobridging and safety
studies will evaluate reduced-dose regimes in low-
income countries where the beneﬁts of lower priced
and more accessible immunization programmes
would be highly beneﬁcial in reducing the burden of
HPV-related disease [46].
Another issue to consider is how to manage the
transition from qHPV or bHPV vaccines to 9vHPV.
The Centers for Disease Control and Prevention has
issued a guidance document on the topic [79]. ACIP
stated that the 9vHPV vaccine may be used to con-
tinue or complete a series started with a different
HPV vaccine product, but no formal ACIP recom-
mendations were released for subjects previously
fully vaccinated with qHPV or bHPV vaccines who
are willing to receive 9vHPV in order to beneﬁt
from broader protection. On the contrary, the
European summary of product characteristics of the
three HPV vaccines states that individuals who
received a ﬁrst dose with a given HPV vaccine should
complete the vaccination course with that same vac-
cine [80, 81]. As we have described, one RCT has
assessed 9vHPV vaccine for safety and immunogen-
icity in prior qHPV vaccine recipients and showed it
to be well tolerated but to elicit an immune response
against HPV types 31/33/45/52/58 lower than in girls
who have never been exposed to HPV [36]. Experts
recently combined available data with their opinion
and judgment and concluded that – considering age
at the start of vaccination, the number of doses
already received and time interval between doses –
9vHPV might be used to complete an incomplete
immunization regimen as well as added to a previous
completed schedule to extend protection [80].
Last but not the least economic considerations
should be mentioned. Several cost-effectiveness exer-
cises projected potential health service savings derived
by introduction of universal 9vHPV immunization
programmes in different epidemiological settings and
under different assumptions of infection transmission,
vaccine efﬁcacy, cross-protection, vaccine coverage,
and costs. As emerges from different scenarios’
analysis, 9vHPV cost-effectiveness as compared with
qHPV will depend on broader protection against
HPV types but also on different duration of protection
and cost per dose [28, 82–84].
Our study has both strengths and limitations. With
regard to the latter, we could not carry out a quanti-
tative pooling of retrieved ﬁndings (i.e. a
meta-analysis) due to the heterogeneity of included
studies. In the long run, when other studies – including
of observational study design – become available, it
will be useful to update the current study, possibly
including implementation and effectiveness data.
Since 9vHPV was licensed, a few narrative reviews
and experts opinions have reported and commented
on available efﬁcacy, immunogenicity, and safety
data, as well as on potential 9vHPV public health
impact [85–87]. However, to the best of our knowl-
edge, this has never been carried out in a systematic
way. In this systematic review, we provide a compre-
hensive and critical update on the published available
evidence as well as on the present status of ongoing
research on relevant clinical and public health aspects
of 9vHPV.
CONCLUSION
The new 9vHPV vaccine appears to be non-inferior to
other existing HPV vaccines in terms of safety and
short-term immunogenicity and efﬁcacy against com-
mon HPV types. The inclusion of additional HPV
types in the vaccine offers great potential to expand
protection against HPV infection and associated dis-
ease burden. However, 9vHPV impact in reducing
the global burden of HPV-related cancer will greatly
depend on vaccine uptake and coverage, availability,
and – last but not least – affordability. For this to hap-
pen, international and national health authorities
should engage in planning, implementing and evaluat-
ing effective immunization programmes, as well as
invest in increasing the knowledge and awareness of
HPV prevention among providers, parents, and peo-
ple receiving the vaccine.
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